Journal
JOURNAL OF PSYCHOSOMATIC RESEARCH
Volume 139, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jpsychores.2020.110262
Keywords
Adult; Anxiety; Clinical epidemiology; COVID-19; Depressed mood; Depressive symptoms; Epidemiology; Pandemic; Scleroderma; Systemic sclerosis
Categories
Funding
- Canadian Institutes of Health Research McGill University
- Scleroderma Canada from Boehringer Ingelheim
- Scleroderma Society of Ontario
- Scleroderma Manitoba
- Scleroderma Atlantic
- Scleroderma Australia
- Scleroderma New South Wales
- Scleroderma Victoria
- Scleroderma Queensland
- Scleroderma SASK
- Scleroderma Association of BC
- Sclerodermie Quebec
- McGill Interdisciplinary Initiative in Infection and Immunity Emergency COVID-19 Research Fund
Ask authors/readers for more resources
Introduction: No studies have reported mental health symptom comparisons prior to and during COVID-19 in vulnerable medical populations. Objective: To compare anxiety and depression symptoms among people with a pre-existing medical condition and factors associated with changes. Methods: Pre-COVID-19 Scleroderma Patient-centered Intervention Network Cohort data were linked to COVID-19 data from April 2020. Multiple linear and logistic regression were used to assess factors associated with continuous change and >= 1 minimal clinically important difference (MCID) change for anxiety (PROMIS Anxiety 4a v1.0; MCID = 4.0) and depression (Patient Health Questionnaire-8; MCID = 3.0) symptoms, controlling for pre-COVID-19 levels. Results: Mean anxiety symptoms increased 4.9 points (95% confidence interval [CI] 4.0 to 5.7). Depression symptom change was negligible (0.3 points; 95% CI-0.7 to 0.2). Compared to France (N = 159), adjusted anxiety symptom change scores were significantly higher in the United Kingdom (N = 50; 3.3 points, 95% CI 0.9 to 5.6), United States (N = 128; 2.5 points, 95% CI 0.7 to 4.2), and Canada (N = 98; 1.9 points, 95% CI 0.1 to 3.8). Odds of >= 1 MCID increase were 2.6 for the United Kingdom (95% CI 1.2 to 5.7) but not significant for the United States (1.6, 95% CI 0.9 to 2.9) or Canada (1.4, 95% CI 0.7 to 2.5). Older age and adequate financial resources were associated with less continuous anxiety increase. Employment and shorter time since diagnosis were associated with lower odds of a >= 1 MCID increase. Conclusions: Anxiety symptoms, but not depression symptoms, increased dramatically during COVID-19 among people with a pre-existing medical condition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available